bioMerieux (FR:BIM) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
bioMerieux, a global leader in in vitro diagnostics, has announced the CE-marking of their new VIDAS VITAMIN B12 TOTAL test, which measures vitamin B12 levels in human serum or plasma. This automated quantitative test, which is essential for diagnosing potential B12 deficiencies, will be available on all VIDAS immunoassay systems. The launch aims to enhance the comprehensive VIDAS test portfolio and is set to begin in select countries at the end of 2024, with a wider release in early 2025.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.
